CSBR 📈 Champions Oncology - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15870P3073
CSBR: Cancer, Research, Software, Data, Mice, Tumors
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey. Web URL: https://www.championsoncology.com
Additional Sources for CSBR Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CSBR Stock Overview
| Market Cap in USD | 66m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2003-01-10 |
CSBR Stock Ratings
| Growth 5y | -36.6% |
| Fundamental | -16.4% |
| Dividend | - |
| Rel. Strength Industry | 891 |
| Analysts | 5/5 |
| Fair Price Momentum | 6.32 USD |
| Fair Price DCF | - |
CSBR Dividends
No Dividends PaidCSBR Growth Ratios
| Growth Correlation 3m | 12.3% |
| Growth Correlation 12m | -69.6% |
| Growth Correlation 5y | -75.3% |
| CAGR 5y | -1.32% |
| CAGR/Mean DD 5y | -0.03 |
| Sharpe Ratio 12m | 0.89 |
| Alpha | 31.11 |
| Beta | 0.66 |
| Volatility | 110.82% |
| Current Volume | 119.2k |
| Average Volume 20d | 61.8k |
What is the price of CSBR stocks?
As of December 21, 2024, the stock is trading at USD 7.51 with a total of 119,179 shares traded.
Over the past week, the price has changed by +18.56%, over one month by +73.73%, over three months by +57.34% and over the past year by +51.01%.
As of December 21, 2024, the stock is trading at USD 7.51 with a total of 119,179 shares traded.
Over the past week, the price has changed by +18.56%, over one month by +73.73%, over three months by +57.34% and over the past year by +51.01%.
Is Champions Oncology a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Champions Oncology is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -16.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CSBR as of December 2024 is 6.32. This means that CSBR is currently overvalued and has a potential downside of -15.85%.
Neither. Based on ValueRay Fundamental Analyses, Champions Oncology is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -16.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CSBR as of December 2024 is 6.32. This means that CSBR is currently overvalued and has a potential downside of -15.85%.
Is CSBR a buy, sell or hold?
Champions Oncology has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy CSBR.
Champions Oncology has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy CSBR.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for CSBR stock price target?
According to ValueRays Forecast Model, CSBR Champions Oncology will be worth about 6.9 in December 2025. The stock is currently trading at 7.51. This means that the stock has a potential downside of -7.86%.
According to ValueRays Forecast Model, CSBR Champions Oncology will be worth about 6.9 in December 2025. The stock is currently trading at 7.51. This means that the stock has a potential downside of -7.86%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 6 | -20.1% |
| Analysts Target Price | 8.8 | 16.5% |
| ValueRay Target Price | 6.9 | -7.9% |